-
-
-
-
-
-
-
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lu
-
-
-
-
-
-
-
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) and Novocure (NVCR) Report Phase 2 Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint
-
-
-
-
-
-
-
Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021
-
-
-
-
-
-
-
Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Zai Lab (ZLAB) Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer, DMC Says Trial Should Continue
-
-
-
-
-
-
-
Entasis Therapeutics Reports Second Quarter 2020 Financial Results and Business Update
-
940,637 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All